Epilepsy trials recruiting in Arkansas

All Epilepsy trials nationally

Cities in Arkansas

Recruiting trials in Arkansas

• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Arkansas: Little Rock
• A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
  NCT06422923 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arkansas: Little Rock
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female) · Arkansas: Little Rock
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
  NCT05716100 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arkansas: Little Rock
• A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
  NCT06769659 · Phase: Phase 2 · Ages: 16 Years to 75 Years · Sex: All (male and female) · Arkansas: Little Rock
• A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
  NCT04462770 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Arkansas: Little Rock
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
  NCT06132893 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arkansas: Little Rock, Rogers
• A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
  NCT05667142 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Arkansas: Little Rock
• An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
  NCT05066217 · Phase: Phase 3 · Ages: 2 Years to 55 Years · Sex: All (male and female) · Arkansas: Little Rock
• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
  NCT07594119 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arkansas: Bentonville
• Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
  NCT05135091 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arkansas: Little Rock